$90.49▼ 0.84 (0.92%)
Real-time prices · US MarketsQ·Score
Buy
7.1 / 10
Analysts see 31% upside to $118.64 consensus target.
earnings contracting 20% year-over-year.
Quality
6.2
Health
8.5
Growth
4.7
Valuation
8.6
Sentiment
7.7
Analyst Target
$118.64
▲ +31.1% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
25.3×
price-to-earnings
Forward P/E
14.9×
next 12 months est.
Market Cap
$157.2B
market capitalization
Div Yield
2.76%
dividend yield
Profit Margin
13.9%
net profit margin
Gross Margin
56.5%
revenue minus COGS
ROE
—
return on equity
Beta
0.78
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$90 — $139
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is ABT a good stock to buy right now?
Based on our Q·Score of 7.1/10, Abbott Laboratories is rated "Buy". Analysts see 31% upside to $118.64 consensus target. Main risk to consider: earnings contracting 20% year-over-year. This analysis is based on fundamentals, analyst consensus, and valuation data, and should not be considered financial advice.
What is the analyst price target for ABT?
The consensus price target for ABT is $118.64, based on the recommendations of 25 Wall Street analysts. This implies 31.1% upside from the current price of $90.49.
Is ABT overvalued or undervalued?
Abbott Laboratories (ABT) appears reasonably valued or undervalued relative to analyst targets and sector peers. It trades at a 14.9× forward P/E ratio. Analysts see 31% upside to their $118.64 consensus target.
When does Abbott Laboratories report its next earnings?
Abbott Laboratories's next earnings report is expected on approximately July 16, 2026.
What is Abbott Laboratories's profit margin?
Abbott Laboratories has a net profit margin of 13.9%, which is solid for most industries. Its gross margin stands at 56.5%, indicating a high-margin business model.
What is ABT's dividend yield?
Abbott Laboratories currently offers a dividend yield of 2.76%, which provides a solid income stream for dividend-focused investors. Dividend yields can change based on price movements and company payout decisions.
Is Abbott Laboratories's revenue growing?
Abbott Laboratories is reporting modest revenue growth of 7.8%. However, earnings declined 19.7%, which warrants monitoring.
How much debt does Abbott Laboratories have?
Abbott Laboratories has a debt-to-equity ratio of 0.27×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet.